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Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder characterized by oculocutaneous albinism, recurrent
bacterial infections and progressive neurological dysfunction. We demonstrate novel heterogenous mutations of CHS1,t h e
responsive gene of CHS, identiﬁed in ﬁve Japanese patients with CHS. Patients 1, 2, and 3 were siblings, and they had albinism
of the skin and hair. They all had a heterogenous two-base deletion (c.5541-5542 del AA, p.Q1847fsX1850) in exon 18. Patient
4 had a heterogenous single-base insertion (c.3944-3945 ins C, p.T1315fsX1331) in exon 10. The patient exhibited severe early-
onset phenotype and suﬀered from hemophagocytic lymphohistiocytosis. Patient 5 had two heterogenous nonsense mutations;
c.7982C>G, p.S2661X in exon 30 and c.8281A>T, p.R2761X in exon 31. The patient suﬀered from infections in childhood and had
visual disturbance and albinism of the skin and hair. The CHS1 mutations described here have not been reported previously.
1.Introduction
Chediak-Higashi syndrome (CHS; MIM 214500) is an auto-
somal recessive disorder characterized by oculocutaneous
albinism, increased susceptibility to pyogenic infections,
defective natural killer (NK) activity, delayed bactericidal
activity of neutrophils, and the presence of giant lysosomes
in many cell types [1–3]. We previously reported that abnor-
mally downregulated protein kinase C activity is responsible
for the impaired cellular functions of polymorphonuclear
leukocytes, ﬁbroblasts and NK cells of CHS mice and
patients [4–9]. The manifestation of CHS may result from
defective traﬃcking of proteins into late multivesicular
endosomes [10]. Most CHS patients die young due to a
lymphoproliferativehistiocytosiscalledtheacceleratedphase
unless they undergo bone marrow transplantation.
The genetic defect resulting in CHS was identiﬁed in
1996 [11, 12]. The human gene, CHS1, was also called LYST
(Lysosomal Traﬃcking Regulator). A similar disorder has
been identiﬁed in beige mice and many other mammalian
species. Human CHS patients and beige mice have homolo-
gous disorders associated with the CHS1 mutation [11–13].
CHS1 consists of 51 coding exons with an open reading
frame of 11,406bp [12]. The CHS1 protein is cytosolic and
is composed of 3801 amino acids with a molecular weight of
429kDa. It is known that CHS1 has a pleckstrin homology
domain, a BEACH domain, and WD-40 repeats in the C-
terminal region [14]. While the exact function of the CHS1
protein has not been elucidated, the protein suggested to
regulatelysosomalsizeorlysosomalﬁssionandaﬀectcellular
events, such as those of nuclear phosphatidylinositol-4, 5-
bisphosphate [15, 16].2 Case Reports in Medicine
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Figure 1: Wright stain of peripheral blood smear of CHS patients, showing polymorphonuclear leukocytes with giant granules (200×).
(a) Patient 1, (b) patient 2, and (c) patient 3.
(a) (b) (c) (d)
Figure 2: Hair shafts under light microscopy (200×). (a) Hair sample of normal Japanese control, showing evenly distributed pigment.
(b) Patient 1, (c) patient 2, (d) patient 3. Hair shafts of CHS patients showing atypical granular pigment pattern.
Thus far, 31 mutations in the CHS1 gene have been
reported, including frameshift, nonsense, and missense
mutations [17–21]. Only ﬁve Japanese CHS patients have
been examined to date. Two patients had a one-base substi-
tution, and one patient had a deletion, whereas no mutation
of the CHS1 gene was detected in the other two patients
[17]. Thus, we attempted to examine the mutations in other
Japanese CHS patients. Here, we report novel heterogenous
mutations of the CHS1 gene identiﬁed in Japanese patients
with CHS.
2. Patientsand Methods
Informed consent for this study was obtained from the
patients or their parents. The study protocol was approved
by the Ethics Committee of the University of Yamanashi.
Patients 1, 2, and 3 (siblings) were 23-year-old male, 20-
year-old female, and 17-year-old female, respectively. Giant
granules were observed in polymorphonuclear cells from
these three patients (Figure 1). They all had albinism of the
skin and hair (Figure 2). However, there was no history of
severe infection in any patient. Their parents were normal
and healthy.
Patient 4 was a 6-year-old female with visual disturbance
and hypopigmentation of the skin and hair (Figure 3).
The diagnosis of CHS was determined by the presence
of myeloperoxidase-positive giant granules in leukocytes
(Figure 4(a)). At the age of 4, she suﬀered from hemophago-
cytic lymphohistiocytosis (Figure 4(b)), which is known as
acceleratedphase.Atthetimeofthestudy,shehadhighfever,
bleeding tendency, hepatosplenomegaly, and pancytopeny.Case Reports in Medicine 3
Figure 3: Hair and skin of patient 4 at the age of 4, showing silvery
hair and hypopigmentaion of skin.
She had low NK activity and decreased bactericidal activity
of neutrophils. In addition, she had been treated with
cyclosporine and steroids and then underwent bone marrow
transplantation.
Patient 5 was a 21-year-old female who suﬀered from
recurrent infections in childhood. At the time of the study,
she had visual disturbance and neurological dysfunction
including gait disturbance. Detailed information on this
patient was not available.
Peripheral blood samples were obtained from ﬁve CHS
patients who had not undergone bone marrow transplan-
tation. Blood samples from parents of patients 1, 2, and
3 were also obtained. Genomic DNA was obtained from
blood samples. Extraction of DNA was performed using
the QIAamp DNA Blood kit (QIAGEN Inc., Valencia, CA,
USA) according to the manufacturer’s protocols. Polymerase
chain reaction (PCR) primer pairs (25–35bp) designed
from intron sequences ﬂanking each exon were used to
amplify genomic DNA segments spanning each exon. For
example, exons 9–10 were ampliﬁed using the F primer 5
 
-ATTTTTGCCACTAGATCTTCTAAATG-3
 ,a n dRp r i m e r
was 5
  -AGAAGCCATTATTATCAACTTTTCAC-3
 . The F
primer of exon 18 was 5
 -TGCTACTGGCCACTAAGGTT-
GTGTGTC-3
 ,a n dRp r i m e rw a s5
 -GACTTTGATGACGA-
GATGAGTATCACTGC-3
 . The F primer of exon 30 was 5
 -
CATTGTATCTATTACATCTAATACACCTGATACAC-3
 ,
and R primer was 5
 -ACGTATAATACAGTCAACATAAA-
ACCTCTATTTCC-3
 .PCRwasperformedusingKOD-Plus-
Ver. 2 according to the manufacturer’s protocols (TOYOBO,
Tokyo, Japan). The PCR products (220–3600bp) were sep-
arated by electrophoresis on agarose gels. DNA was isolated
from each band using the QIAquick Gel Extraction kit (QIA-
GEN Inc.). Direct sequencing using dye termination cycle
sequencing was performed at FASMAC Co., Ltd. (Atsugi
City, Kanagawa, Japan). The mutations were analyzed using
Sequence Scanner Ver. 1 (Applied Biosystems, Tokyo, Japan)
and were also checked at the cDNA level. For this purpose,
total RNA was extracted from blood samples using Isogen-
LS (Nippon Gene Co., Ltd., Tokyo, Japan) according to
the manufacturer’s protocols. cDNA was synthesized using
PrimeScript reverse transcriptase (Takara Bio. Inc., Shiga,
Japan), and PCR was performed as described above.
3.MolecularAnalysis
All 51 exons of the CHS1 gene of the ﬁve patients from
three families were sequenced, and four patterns of novel
heterogenous mutations were identiﬁed. In patients 1, 2,
and 3, a two-base deletion (c.5541-5542 del AA) in exon 18
resulted in a frameshift mutation that eventually led to the
formation of a stop codon (p.Q1847fsX1850) (Figure 5(a)).
Thesecondmutationwasnotfoundinthecodingexons.The
same heterogenous mutation was detected in their father. In
their mother, no mutation was found in the CHS1 exons.
Since their parents had no symptoms, it was possible that
the second mutation lies in the intron sequence or splice
mutation site. It was also possible that this mutation shows
a mild phenotype associated with heterozygosity. Another
possibility is the mutation in another gene, which aﬀects the
generation of lysosome-related organelles.
In patient 4, we detected a heterogenous one-base (C)
insertion (c.3944-3945 ins C) in exon 10, resulting in a
frameshiftmutationthatledtotheformationofastopcodon
(p.T1315fsX1331) (Figure 5(b)). The second mutation was
not found in any coding exon. The blood samples of her
parents were not available.
Inpatient5,twoheterogenousmutationswereidentiﬁed;
C-G substitution (c.7982 C > G) in exon 30 resulted in
a nonsense mutation (p.S2661X) (Figure 5(c)), and A-T
substitution (c.8281A > T) in exon 31 resulted in a nonsense
mutation (p.R2761X) (Figure 5(d)). Blood samples of her
parents were not available.
4. Discussion
The sequence pattern of CHS1 mutations described here has
not been reported previously. All mutations were predicted
to halt production of the complete CHS1 protein. Karim
et al. [17] demonstrated that missense mutant alleles that
likely encode CHS1 polypeptide with partial function were
found in adolescent and adult forms of CHS, whereas
functionally null mutant CHS1 alleles were found in case
with severe childhood CHS. Westbroek et al. [19] also
demonstrated that cellular defects in CHS correlate with the
molecular genotype and clinical phenotype. In the present
study, patient 4 and 5 exhibited early-onset CHS and were
predicted to have a truncated CHS1 protein. Although the
other three patients (patients 1, 2, and 3) were also predicted
to have the truncated protein, they had clinically milder
forms of CHS. In these patients, only single mutation in the
CHS1 coding exons was detected. Since these patients were
relatively healthy, it is possible that the mutant protein is
acting asa dominant negative, resulting in a mild phenotype.
In addition, we cannot exclude a possibility that the second
mutation lies in the intron sequence or splice mutation site.
However, the real reasons remain unknown, as we could
not examine protein levels in these patients. In the previous
report [17], no mutation in the CHS1 gene was found in
10 CHS patients, and only single mutations were found in4 Case Reports in Medicine
(a) (b)
Figure 4: Bone marrow aspirate smear of patient 4, showing (a) myeloperoxidase-positive giant granules and (b) hemophagocytosis.
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Figure 5: The cDNA sequence patterns of CHS1 mutations. (a) Patients 1, 2, and 3: frameshift mutation in exon 18, c.5541-5542delAA, p.
Q1847fsX1850.Thesethreepatientsweresiblings.ThesamesequencepatternofcDNAwasobservedintheirfather.(b)patient4:Frameshift
mutation in exon 10, c.3944-3945 ins C, p.T1315fsX1331. (c) patient 5: Nonsense mutation in exon 30, c.7982 C > G, p.S2661X. (d) patient
5: Nonesense mutation in exon 31, c.8281 A > T, p.R2761X.
4 CHS patients. These ﬁndings suggest a possibility that the
mutation lies in a gene other than CHS1, which aﬀects the
generation of lysosome-related organelles. In patient 5, two
heterogenous nonsense mutations were identiﬁed. Recently,
two heterogenous nonesense mutations in the CHS1 gene
were reported in an African-American patient [20]. In that
report, the patient exhibited severe childhood CHS. These
ﬁndings support that the functionally null CHS1 mutant
alleles are detected in severe childhood CHS.
In Japanese CHS patients, only three mutations have
beenidentiﬁedsofar,whereasnomutationinthe CHS1gene
was found in two other patients [17]. We have described
four patterns of novel mutations that are expected to result
in a truncated CHS1 protein. However, the relationship
between these mutations and the phenotype remains to be
resolved. Examination of a large number of CHS patients
will be required to clarify the genotype-phenotype correla-
tion.Case Reports in Medicine 5
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